Wearable Injectors Market: Increasing demand for biologics and mAbs

[Snehal Shaha]

A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). According to PhRMA (Pharmaceutical Research and Manufacturers of America), as many as 907 biologics were in development in 2013; the number of biologic drugs in development is continuing to increase exponentially, with more than 2,700 remedies in development as of mid-2017, triple the 907 in development in 2013. mAb-based biotherapies account for 50% of the top 100 drugs and are projected to maintain a dominant position in the pharmaceutical market.
The global Wearable injectors market is projected to reach USD 11.6 billion by 2026 from USD 7.3 billion in 2021, at a CAGR of 9.9% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004
Market Segmentation:
By type, the global market is segmented into on-body injectors and off-body injectors. The on-body injectors segment accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.
Based on technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously.
Based on therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson's disease, thalassemia, and primary immunodeficiency disorders). The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment.
Based on end user, the market is segmented into hospitals and clinics and home healthcare settings. The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment.
Regional Analysis: -
The wearable injector market in North America accounted for the largest market during the forecast period. The large share of North America in this market is to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region. However, the Europe market is estimated to grow at the highest CAGR during the forecast period owing to factors such as the Increasing prevalence of chronic diseases, Government support for drug development in Germany, Rising focus on biosimilar innovation in the UK, Favorable reimbursement scenario for various treatment options in France.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004
Top Key Players :-
Prominent players in the wearable injectors market include Becton, Dickinson and Company(US), Ypsomed(Switzerland), Amgen(US), Subcuject(Denmark), Enable Injections, Inc(US), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland).